Barcelona, July 26, 2022. -Investment in health startups in the BioRegion of Catalonia set a new record in the first half of the year: €296 million, more than all funding secured in 2021 (€238 million). This period (January to July) was the best ever, fueled once again by venture capital, which totaled €258 million, or 87% of the capital raised, followed by the stock market, public grants and crowdequity.
Only a few months from completion, Boost4Health has helped over 50 startups from the BioRegion in their internationalization. Beyond measuring the number of companies or how they access new markets thanks to the grants received, this post goes a step further and provides an overview of the possible impact of the positive effect on the health of people and patients.
We get a first-hand look at the experience of Catalan digital therapeutics companies (DTx) with the healthcare system and take advantage to ask what needs to improve, in their opinion, to facilitate adoption of innovative projects like theirs.
Last March, the SARS-CoV-2 pandemic put mobility and social life on hold in most of the world, however in biotech and healthcare, things didn’t stop at all. It was just the opposite, in fact, with activity ramping up. But the pandemic has forced the sector to turn to new ways of working and, in some cases, seem they’re here to stay.